This ongoing work was published on the web before print publication. An abstract of the paper is offered by the journal’s website. Watch abstract. This function was published online in advance of print publication. An abstract of the paper is offered by the journal’s website. Look at abstract. An abstract of the paper is available through PubMed. Watch abstract.. Bright quantum dots help fundamental cancer biology studies Though there is little doubt that nanoscale devices are going to play a critical part in improving cancer detection and treatment over another five to ten years, nanoparticles are already having a major effect on the way that cancer biologists study the procedures that be fallible within malignant and metastatic cells. By firmly taking advantage of the unique optical and various other physical properties of nanoscale components, researchers have made a veritable toolbox of nanoparticle probes that may monitor the fate of cells and actually individual molecules in complex environments, starting the hinged door to an array of new experiments designed to better understand the malignancy process.The completion of preclinical studies is a key milestone for our company, and implies that we are today ready to prepare our first IND for Alzheimer’s disease and move towards human trials, stated Harvey Lalach, President of ANAVEX. Our novel approach is based on ANAVEX’s expertise and leadership in neuro-scientific sigma receptors and our extremely productive drug discovery platform. This approach has made it possible for us to develop the first in a series of novel, new-generation drugs using sigma ligands to treat a range of CNS and oncological conditions. We are thrilled to end up being advancing this 1st novel compound for Alzheimer’s disease toward clinical trials.